Evidence map›Paper›PMID 26003326›Full record

ArticleDiabetologia2015

Future of muscle research in diabetes: a look into the crystal ball.

Michael Roden

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. TelmisartanFrontiers in pharmacology · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michael RodenDepartment of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University Düsseldorf, c/o Auf´m Hennekamp 65, D-40225, Düsseldorf, Germany, michael.roden@ddz.uni-duesseldorf.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In type 2 diabetes, skeletal muscle is not only responsible for early metabolic abnormalities, but its contractile activity also offers an efficient prevention and treatment strategy. This outlook into the coming decades summarises challenges and opportunities for translational research on skeletal muscle in diabetes and related diseases. Currently, our understanding of the interactions between myocellular networks, the master regulators of resting metabolism, and muscle's position within multi-organ crosstalk, is incomplete. In the face of an ageing population, changes within muscle tissue appear to be the predominant mechanisms responsible for sarcopenia, but the relative roles of obesity and ageing as driving forces of its development are less clear. To address these research questions, innovative approaches to optimising exercise training or minimising sedentarism will need to be devised and tested in large-scale standardised prospective studies. Finally, another major challenge will be the identification and evaluation of muscle targets to prevent and treat metabolic diseases. This is one of a series of commentaries under the banner '50 years forward', giving personal opinions on future perspectives in diabetes, to celebrate the 50th anniversary of Diabetologia (1965-2015).

Indexed as

ResearchAnimalsDiabetes Mellitus, Type 2ExerciseHumansMuscle, SkeletalObesity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.